Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

This study tests a new drug called AZD3632 — alone or combined with other cancer medicines — for people with advanced blood cancers, including certain types of leukemia and a bone marrow condition called myelodysplastic syndrome (MDS). These cancers have specific genetic changes that cause abnormal growth signals in the cells. **You may be eligible if...** - You have been diagnosed with acute leukemia or MDS with specific genetic mutations (KMT2A rearrangement, NPM1 mutation, or similar HOX pathway changes) - Your cancer came back or stopped responding to standard treatments like chemotherapy or hypomethylating agent therapy - Your white blood cell count is below 25,000 - You are physically able to carry out basic daily activities (low-to-moderate performance status) - You have at least 8 weeks life expectancy **You may NOT be eligible if...** - You have Burkitt lymphoma, Burkitt leukemia, or Acute Promyelocytic Leukemia (APL) - Leukemia has spread to your brain or testicles - You still have significant side effects from a previous cancer treatment - Your potassium or magnesium levels are abnormal Talk to your doctor to see if this trial is right for you.